Fingerprint
Dive into the research topics of 'Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically